Vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3

摘要

The vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3. The vaccine is produced in Lactococcus lactis as a secreted recombinant hybrid protein. Experiments show that the Glutamate-rich protein part of the hybrid increases the overall antibody response. - Immunizations with the hybrid protein consistently generates a stronger antibody response against the individual Glutamate rich protein and Merozoite surface protein 3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites.